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Background and Aims: Mucosal lesions refractory to biological treatments represent
unmet needs in patients with inflammatory bowel disease (IBD) that require new treatment
modalities. We developed and characterized a new endoscopic drug-eluting hydrogel
(CoverGel) with proven efficacy in acute and chronic experimental colitis (EC) in rats.
Methods: CoverGel was developed based on appropriate rheological, drug release,
gelation, structural, and degradation property capacities to allow endoscopic application.
Experimental colitis (EC) was induced by TNBS application in rats. In acute EC 40,
rats were randomized in five groups (eight each): Sham, Control, CoverGel, CoverGel
+ Infliximab (IFX) and CoverGel + Vedolizumab (VDZ). In chronic EC, 12 rats were
randomized in two groups (six each): IFX s.c. and CoverGel + IFX. Endoscopic,
histological, and blood test were performed during follow-up to evaluate clinical success.
Antibodies to IFX (ATIs) were evaluated in chronic EC animal study.
Results: CoverGel is a biocompatible and bioadhesive reverse thermosensitive gelation
hydrogel with a macroporous structure and drug release capacity. In acute EC animals
treated with CoverGel + IFX or CoverGel + VDZ showed significantly clinical success
(weight recovery, mucosal restoration, and bacterial translocation) as compared with
controls and animals without a bioactive drug. In a chronic EC animal study, clinical
efficacy was comparable in both groups. Levels of ATIs were significantly lower in animals
treated with CoverGel+ IFX vs. IFX s.c. (0.90± 0.06 µg/mL-c vs. 1.97± 0.66 µg/mL-c,
p = 0.0025).
Conclusions: CoverGel is an endoscopic vehicle to locally deliver biological drugs with
proven efficacy in acute and chronic EC in rats and induce less immunogenicity reaction.
Keywords: drug-eluting, experimental colitis, endoscopic shielding technique, hydrogel, endoscopy
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INTRODUCTION
Interventional inflammatory bowel disease (IBD) endoscopy has
an expanding role in the era of biologic therapy. A significant
number of patients have mucosal lesions refractory to biological
treatments despite the availability and growing use of anti-
tumor necrosis factor (TNF), anti-integrin, anti-interleukin, and
new small-molecule (1, 2). These drugs have changed the way
of treating IBD patients, but those situations represent unmet
needs that require new treatment modalities to prolong the
intervention-free period. An endoscopic shielding technique
with hydrogels has been proposed by our group as a less invasive
approach to reduce or postpone the need for surgical resection
(3, 4).
Hydrogels or hydrophilic gels are cross-linked polymeric
three-dimensional networks which present soft tissue-like elastic,
non-toxic, and biodegradable properties while being responsive
to stimuli (5–8). Nowadays we do not have any valid endoscopic
treatment to IBD mucosal lesions in patients with refractory
or loss of response to biological therapy. The purpose of the
present study was to develop and characterize a new endoscopic
drug-eluting platform and test its efficacy in acute and chronic
experimental colitis in rats.
MATERIALS AND METHODS
Characterization of the Drug-Eluting
Platform
We have developed a new hydrogel (CoverGel) comprising
specific amounts of hyaluronic acid (HA), methylcellulose (MC),
and Poloxamer Pluronic-F127 (F127). This platform has been
patented (WO 2018/019881 A1). The composition of CoverGel
is based on the combination of different substances to create this
solution, which can be prepared before the procedure.
Our goal was to improve the beneficial effects of HA
onto the colonic mucosa by adding different substances to
increase biocompatibility, bioadhesive, and bioactive properties
and make it suitable to be administered through the endoscope’s
working channel. For this, we evaluated different aspects:
rheological properties (viscosity, adherence, andmicrostructure),
gelation, degradation, drug absorbance, drug release, and
biocompatibility. Four different original combinations (colon
dressing, CD) of prototypes of materials (CD1, CD2, CD3, CD4)
were tested for viscosity, adhesion force, and microstructure.
The best composition for the drug-eluting platform was different
percentages of HA, MC, and PF127. All compounds of the
product are well-known and have proven safety. The composition
of the invention is biodegradable, is easy to administrate, remains
adhered to the mucosal lesion, and is a drug-release composition.
Rheological test: (i) Viscosity was evaluated in a rheometer
(Haake RheoStress; Thermo Fisher Scientific, Waltham, MA,
USA) with a C60/1◦ Ti probe and a gap set of 0.053mm. The
rotation ramp went from 0–300 s−1 in 30 s. For each study,
Viscosity (η) was measured as a function of shear rate (γ) at 22◦C
(room temperature) and 37◦C (body temperature), (ii) Adhesion
was measured with a Texture Analyzer TA.XT Plus (Stable Micro
Systems, Surrey, UK). A 40-mm (diameter) disk was compressed
into the gel and redrawn. The velocity of the insertion assay was
1 mm/s, and the withdrawn distance was 9mm. Adhesion was
determined at 20 and 37◦C, and the (iii) microstructure of the
hydrogel was assessed with scanning electron microscopy (SEM).
Gelation assay was carried out to determine the behavior of
the hydrogel under UV light radiation at different temperatures.
The following scenarios were tested: (i) 1mL of hydrogel and 15
µL of photo-initiator solution were mixed and placed on a petri
dish. The hydrogel was heated at 37◦C for 30min, and gelation
was tested. Next, the hydrogel was cooled; (ii) 1mL of hydrogel
and 15 µL of photo-initiator solution were mixed and placed on
a petri dish. The dish was placed under ultraviolet light 2,000
mV/cm2 for 3min (AnalytikJeta UVP Crosslinker), keeping the
temperature below 20◦C. The hydrogel was heated at 37◦C for
30min, and gelation was tested. Next, the hydrogel was cooled;
(iii) 1mL of hydrogel was placed on a petri dish. The hydrogel
was heated at 37◦C for 30min, and gelation was tested. Next,
the hydrogel was cooled; (iv) 1mL of hydrogel was placed on
a petri dish. The dish was placed under ultraviolet light 2,000
mV/cm2 for 3min, keeping the temperature below 20◦C. The
hydrogel was heated at 37◦C for 30min, and gelation was tested.
Next, the hydrogel was cooled. For hydrogel observation after the
irreversible episode, they were lyophilized at 50◦C for 96 h and
were examined by Field-Emission Scanning ElectronMicroscopy
(FE-SEM) on a FEI Quanta 650microscope using aluminum tape
as support.
Degradation assay was performed to understand the
degradation rate of our hydrogel under different conditions
that would try to mimic the different conditions found in the
gastrointestinal tract; 1mL of hydrogel was irreversibly gelified
and then submerged in 10mL of one of the following solutions:
PBS pH= 7, PBS pH= 3, PBS pH= 9, PBS pH= 11 and rat feces
bacteria culture on Luria-Bertani (LB), and broth at a starting
range of 105 CFU/mL. The piece of gelified hydrogel was weighed
before the submersion (Wo) and then on set date points (Wt)
until complete dissolution of the hydrogel or until 1 month under
the conditions was reached. At each time point, the medium was
also changed when the weighing took place.
Drug absorbance and drug release kinetics of the hydrogel
was also evaluated in vitro with mathematical models to study
the capacity of our hydrogel to both release and absorb molecules
of different molecular weight, in order to further study the
capability of this hydrogel to act as a drug-eluting platform. For
these experiments, we worked with two molecules: (i) Trypan
blue, which has a molar mass of ∼ 960 Daltons; and (ii) bovine
serum albumin (BSA), which has a molecular weight of 66.5 kDa.
For the Trypan blue experiments, first, a calibration curve was
prepared by measuring the absorbance (λ = 450 nm) of different
concentrations of Trypan blue diluted in water using a Uv-Vis
spectrophotometer (Varioskan Flash, Thermo). SkanIt Software
2.4.1 was used to analyze results. Then, the curve equation was
obtained: y = 6234.9x + 0.1008. R2 = 0.99349. Absorbance
and release of BSA was evaluated with the Bicinchoninic acid
(BCA) Protein Assay Kit (PierceTM, Thermo Scientific) following
manufacturer’s instructions.
To incorporate substances inside the hydrogel, 0.25mL of
gelated hydrogel was submerged in 5mL of 0.0005 mg/mL
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Trypan blue or 2 mg/mL BSA. Hydrogels incorporated the
solution at room temperature for 48 h. To calculate the amount
of substance incorporated into the matrix of the hydrogel, the
following equation was used:
Incorporating efficiency (%) =
V1 • C1− V2 • C2
V1 • C1
× 100
Where V1 is the original volume of the substance solution (mL);
V2, the remaining volume of the substance solution after 48 h
(mL); C1, the initial concentration of the substance (µg/mL); and
C2, the remaining concentration of the substance (µg/mL).
Hydrogels were withdrawn from the solution and placed in
a release medium (PBS). At specific time points, the amount of
substance released into the medium was evaluated as mentioned
before. The kinetics of drug release from the hydrogels was
studied with three different models to asses which one fitted best
with the release data from our experiments. The three different
models were the following:
Higuchi release model :Mt = Kht
1/2
Zero− order release model :Mt = K0t
First− order release model :Mt = 1− e− K1t
Where Mt is the fraction of drug released at each time point
(t), and Kh, K0, and K1 are the Higuchi release kinetic constant,
the zero-order release kinetic constant, and the first-order release
kinetic constant, respectively.
Lastly, the drug release mechanism was analyzed using the
Korsmeyer-Peppas model:
F =
(
Mt
M
)
= Kmt
n
This is a semi-empirical model used when the exact mechanism
is not known or in the case when more than one mechanism
is involved in the drug release; where F is the fraction of drug
released at time (t), Mt is the amount of drug released at time (t),
M is the total amount of drug in the hydrogel, Km is a kinetic
constant, and n is the release exponent, indicative of the drug
release mechanism. n is estimated from linear regression of log
(Mt/M) vs. log t; when determining the n exponent, only portions
of the release curve ≤ 60% should be used.
Biocompatibility assays (cytotoxicity, hemolysis, and acute
toxicity) were first performed to check the possible cytotoxicity
induced by CoverGel, carrying out a co-culture of a cell
line with different conditions involving our hydrogel. The
cell line chosen for these experiments was Caco-2 (ATCC R©
HTB-37TM), a human colorectal adenocarcinoma cell line. For
cytotoxicity evaluation, 3 × 104 cells/cm2 were cultured in 24-
well cell plates under the following conditions: Normal culture
medium (DMEM medium supplemented with 10% fetal bovine
serum, 1% L-glutamine, and 1% penicillin/streptomycin) as a
positive control; Normal culture medium supplemented with
10% dimethyl sulfoxide (DMSO) as a negative control; and
Normal culture medium supplemented with 1%-2%-5%-10%-
15% of hydrogel v/v. Cells were cultured at 37◦C and 5% CO2
for 24, 48, 72, and 96 h. At specific time points, cell viability was
evaluated using Resazurin Sodium Salt (Sigma-Aldrich).
Hemolysis test was done in vitro. Two milliliters of gelified
hydrogel were placed in 20mL of sterile saline and incubated
for 72 h at 37◦C. Afterward, the solution was collected and
filtered with a 0.22-µm membrane; 2-mL blood samples were
freshly collected from six male Sprague–Dawley rats into an
anticoagulant tube and gently mixed. Blood was then diluted with
2.5mL of saline. For the hemolysis test, 10mL of the hydrogel
extraction, distilled water, and saline were poured in 50mL
test tubes and placed at 37◦C for 30min. After that, 0.2mL of
diluted blood was added to each test tube with gentle shaking,
and the solution was placed at 37◦C for 1 h. The absorbance of
the samples after 1 h was evaluated with a spectrophotometer
(Varioskan Flash, Thermo) at 545 nm. SkanIt Software 2.4.1 was
used to analyze results. Hemolysis ratio (%) was calculated with
the following formula:
A hydrogel− A saline solution
A distilled water− A saline solution
× 100
The acute toxicity of CoverGel was evaluated in male Sprague–
Dawley rats, 7 months of age (400–550 g). Animals were divided
in three groups: two subjects and a control group. Each group
contained three animals, and a total of nine animals were
used. Rats from the subject groups were injected with 10
mL/kg of our hydrogel into the abdominal cavity, and rats
from the control group were injected with 10 mL/kg saline
into the abdominal cavity. Animals were observed daily after
administration and evaluation of general conditions (activity,
hair, feces, behavior, and other clinical signs), body weight,
and mortality were done. Animals were euthanized at 3 and 7
days with anesthetic overdose, and major organs (heart, liver,
spleen, lung, and kidney) were extracted, evaluated, and fixed
in a 10% formaldehyde solution. Organs were then stained
with hematoxylin/eosin for histopathological evaluation. Blood
was also extracted, and hematological and biochemistry analyses
were performed.
The effect of subcutaneous implantation of CoverGel was
evaluated in sixmale Sprague–Dawley rats, 7months of age (420–
500 g). Rats maintained the subcutaneous implantation for 10
days. Under anesthesia, a 2-cm incision was done on the dorsal
back of the rat, and 0.5 g of gelified hydrogel was implanted
subcutaneously. The incision was then sutured, and rats were
allowed to recover with food and water ad libitum. After 10 days,
rats were euthanized, and the hydrogel was extracted and cut
in two; one piece was placed in Carnoy solution (60% ethanol,
30% chloroform, and 10% glacial acetic acid) for histological
evaluation and the other piece was lyophilized (Christ Loc-1m,
B. Braun) and evaluated using SEM.
Endoscopy
All endoscopic evaluations were carried out using an Olympus
Video bronchoscope EVIS EXERA II (BF-1T180)-type
endoscope with an outer diameter of 6.0mm and a working
channel diameter of 3.0mm. Room air was used for insufflation
during the endoscopy. Endoscopic application of hydrogel
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was done by positioning the tip of the catheter over the
mucosal lesions.
Acute Experimental Colitis (EC) Animal
Study
The EC animal model was induced by the rectal instillation
of 0.6mL of 3.5% TNBS solution in 50% ethanol (Day 0).
The peak of colitis was established 3 days post administration
(Day 3), and animals were examined to evaluate the affection
and apply treatments. Forty male Sprague–Dawley rats (Harlan
Laboratories Models SL, Barcelona, Spain) weighing 250–300 g,
which lost at least 8% of the original weight (Day 0) and showed
a circumferentially affected area at day 3, were included in this
study. Animals were randomized in five groups: (i) Sham group,
healthy animals with no administration of TNBS; (ii) Control
Group, animals with EC treated with 1mL of saline, through the
endoscope; (iii) CoverGel group, animals with EC treated with
CoverGel without active substance; (iv) CoverGel + Infliximab
(IFX) group, animals with EC treated with CoverGel with IFX,
1 mg/mL; (v) CoverGel + Vedolizumab (VDZ) group, animals
with EC treated with CoverGel with VDZ, 1 mg/mL. A total
amount of 1.5mL of CoverGel was applied in groups iii, iv, and v;
thus, the dosage of the drug applied to groups iv and v was 1.5mg
of IFX or VDZ, respectively.
Animals were weighed and underwent colonoscopy on days 0,
3, and 7. Blood was extracted by a small cut on the tail, and serum
was kept frozen for future evaluations. Ponderal evolution was
studied as the variation (1) of original weight at day 0 for each
rat. Four days after treatment (Day 7), animals were euthanatized
by an anesthetic overdose, and liver and colon were evaluated.
Ulcer site samples were cut and placed in formaldehyde for H/E
staining and blinded histopathological evaluation. Histological
study evaluated the maintenance of the intestinal architecture
and the inflammatory cell infiltrate in a 0–3 scale for both
characteristics and a final 0–6 scale. The scoring system (Table 1)
followed was extracted from Ulrike Erben et al. (9). Liver was
retrieved under sterile conditions and 0.5 g was places in 1mL
of saline and homogenized. Then, 0.1mL of the homogenate
was cultured on a LB Agar petri dish at 37◦C for 24 h. The
appearance of CFU was evaluated as a way to establish bacterial
translocation to the liver, a marker, or a weak intestinal wall due
to inflammation.
Chronic EC Animal Study
All animals included in this protocol underwent four rounds of
TNBS colitis induction in the same fashion as the acute model,
thus, induction was done on days 0, 7, 14, and 21; treatments were
given on days 3, 10, 17, and 24, and euthanasia was performed
on day 28. Twelve male Sprague–Dawley rats were included.
Animals were randomized in two groups: (i) IFX s.c. group,
animals with EC treated with 5 mg/kg of IFX subcutaneously; (ii)
CoverGel + IFX group, animals with EC treated with CoverGel
+ IFX (1 mg/mL). A total amount of 1.5mL of CoverGel was
applied per animal; thus, the total amount of drug administered
to group ii was 1.5mg of IFX per animal at each day of
treatment. All assessments were carried out the same way as
in the acute EC study. Animals underwent endoscopic follow-
up at days of induction, days of treatment, and the day of
euthanasia. Furthermore, antibodies to IFX (ATIs) in serum were
also evaluated. To separate ATIs from IFX as they might be found
on blood, a protein G column and an acidic buffer treatment
were used; 600 µL of a 1:10 dilution of serum was applied
onto the protein G column (Ab Spin trap; GE Healthcare) and
washed. Trapped ATIs were eluted with 400 µL of elution buffer
(0.1M Glycine-HCl, pH 2.7) which releases proteins trapped in
the protein G column and, at the same time, dissociates ATI’s-
IFX complexes. Samples were eluted into neutralizing buffer (1M
Tris-HCl pH 9) containing an IgG concentration of 20µg/mL to
prevent the reformation of immune complexes. Then, with the
samples obtained from the protein G column, a 96-well plate
was coated with 200 µL/well O/N at 4◦C or for 1 h at 37◦C.
Plates were washed with washing buffer (PBS 0.1% Triton), and
200µL/well horseradish peroxidase-conjugated Infliximab (HRP
conjugation Kit, Abcam) (0.2µg/mL IFX-HRP) was added for
30min at room temperature, protecting the plate from direct
light. The plate was further washed, and finally, a substrate
solution (3,3′,5,5′-Tetramethylbenzidine/H2O2 50% vol/vol) was
added to the microplate. The enzyme reaction yields a blue
product that turns yellow when stop solution (2M sulfuric acid)
is added. The intensity of the color measured is in proportion
of the quantity of ATIs bound in the initial step; this intensity is
measured by determining the optical density of each well using a
microplate reader at 450 nm with a wavelength correction set to
540 nm using a spectrophotometer (Varioskan Flash, Thermo).
SkanIt Software 2.4.1 was used to analyze results.
Statistical Study
All values are expressed in median ± range unless otherwise
stated. The comparison of groups was done using two-way
ANOVA and Tukey’s multiple comparison test as a post hoc.
Release kinetics was studied using mean values of 6 different
experiments and a non-linear regression fit to each different
model equation. The Graphpad Prism 6.0 software was used to
perform analysis.
Animal Care
All animals were obtained from ENVIGO. All protocols were
reviewed by the Animal Experimentation Ethics Committee of
the Hospital Universitari Germans Trias I Pujol (registered as
B9900005) and approved by the Departament d’Agricultura,
Ramaderia, Pesca, Alimentació i Medi Natural of the Catalan
Regional Government (protocols number 8,585 and 10,235)
according to current national and European Union legislation
regarding the protection of experimental animals. Rats were
supervised daily in order to ensure animal welfare and
euthanized, if required, by anesthetization with isoflurane. All
animals had free access to water and food ad libitum. After any
procedure carried on the animals, 200 mg/kg of paracetamol
was administered intraperitoneally, and animals were monitored
daily. Normal parameters of well-being such as hair health and
secretions were analyzed.
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TABLE 1 | Histological scoring system for the experimental colitis animal models.
Inflammatory cell infiltrate Intestinal architecture
Severity Extent Score 1 Epithelial changes Mucosal architecture Score 2
Mild Mucosa 1 Focal erosions 1
Moderate Mucosa and submucosa 2 Erosion ± Focal ulcerations 2
Marked Transmural 3 Extended ulcerations ± granulation tissue ± pseudopolyps 3
Sum of scores 1 and 2: 0–6
FIGURE 1 | Rheological evaluations of the four original colon dressings (CDs). (A) Adhesion force evaluated at 22◦C and 37◦C expressed in mN/s. (B)
Viscosity evaluated at 22◦C (black line) and 37◦C (red line) expressed in pascals. (C) Scanning electron microscopy images of CD1, CD3, and CD4 (top three pictures)
and CD2 (bottom pictures).
RESULTS
Development of the Drug-Eluting Platform
All hydrogels showed a similar adhesion force at 22◦C, but
when temperature was raised, adhesion force of only CD2
(CoverGel) was highly increased from −25 to −3,993 mN/s
(Figure 1A). Viscosity (η) of all samples was similar at 22◦C,
but when temperature was increased to 37◦C, the viscosity of
CD2 was increased from < 1 Pa·s at 22◦C to 1,500 Pa·s at 37◦C
(Figure 1B). In addition, the morphology of irreversible hydrogel
was evaluated by SEM observing that it is formed by a structured
network with well-defined porous distribution ranging from 50
to 300µm (Figure 1C).
Reversible and irreversible gelation of the hydrogel was
acquired. Hydrogel can be given smoothly through a catheter
(diameter 2.0–2.2mm) by applying a force of 370 mmHg
(0.48 atmospheres). Hydrogel was also stable during 30 days
at physiological-like conditions (Figure 2A). For Trypan blue,
the incorporating efficacy was 58.96 ± 2.8%, and for BSA,
24.09 ± 4.34% (mean ± SD). Drug release from hydrogel was
related to the concentration of the drug in the medium, which
followed a Fickian diffusion. The release kinetics model that
best fits our results is the Higuchi release model, being the
final equation obtained for our results: for Trypan blue (Mt =
0.05760t1/2; R2 = 0.8986) and for BSA (Mt = 0.1369t1/2; R2 =
0.9167). The release exponents (n) were 0.4338 for Trypan blue
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FIGURE 2 | Characterization of CoverGel. (A) Degradation of the hydrogel
when placed for 30 days under different conditions ( PBS pH3, PBS
pH7, PBS pH9, PBS pH 11, and bacterial culture). Graph
represents weight of hydrogel over days. (B) Drug-release kinetics for
Bovine serum albumin and Trypan blue. Graph represents concentration
of substance on release medium (Mt) over time. Lines represent the different
mathematical models tested.
TABLE 2 | Coefficient of determination (R2) of our data to the three kinetic release
models (zero-order release model, first-order release model, and Higuchi release
model) and for the drug release mechanism (Korsmeyer-Peppas model).
Sample 0-order R2 1st-order R2 Higuchi R2 Korsmeyer-Peppas
Tryp. B 0.2022 0.3361 0.8986 0.9169
BSA 0.5393 0.8324 0.9167 0.9171
and 0.5116 for BSA (Figure 2B). Table 2 shows the correlation
coefficient of the different kinetic models and the Korsmeyer-
Peppas mechanism model.
CoverGel showed good biocompatibility, both in the in
vitro and in vivo studies. Caco-2 cells cultured with different
concentrations of our hydrogel showed increased proliferation,
reaching a top at 10% when compared to the positive control of
the experiment (normal culture medium) (Figure 3). Hemolysis
rate caused by our hydrogel on blood from three different rats
was 2.829± 1.135%.
There was no sign of inflammation, toxicity, or tissue
malformation on major organs induced by the hydrogel.
Macroscopic evaluation of major organs didn’t show any signs
of abnormalities, and organ weight with respect to total body
mass didn’t present any significant differences (Figure 4A). Heart
tissue didn’t show signs of toxicity; cardiac myocytes maintain
a good arrangement; and no hemorrhage, inflammation or
necrosis is observed. In the liver, no hepatocellular degeneration
occurs, and there isn’t an abnormal neutrophil, lymphocyte,
or macrophage infiltrate in the tissue. Tissue structure from
spleen, kidneys, and lungs is maintained as well (Figure 4B).
Subcutaneous placement of 0.5 g of the hydrogel showed a
synovial metaplasia, a capsular surface covered by fibrohistiocytic
cells that are grouped forming pseudovilli. No toxicity or
inflammation was seen in the surrounding tissue, meaning that
the body responded by encapsulating the hydrogel as it would
do with a foreign body, but no rejection response was triggered
(Figure 4C). At the time of placement, hydrogels weighed 0.5 g;
when extracted, the weight was 0.95 ± 0.06 g. The platform
was able to maintain its porosity and inner structure. No cell
infiltration was seen 10 days after subcutaneous placement
(Figure 4D).
Efficacy of the Drug-Eluting Platform in
Acute EC Animal Study
At day 3, all animals presented an entire circumferential
affectation of the wall. Macroscopic and endoscopic evaluations
at day 7 showed a completemucosal restoration (vascular pattern,
ulceration and friability) in the CoverGel + IFX and CoverGel
+ VDZ groups, whereas in the CoverGel group, this mucosal
restoration was not complete. However, all treated groups clearly
showed less mucosal damage than the Control group (Figure 5).
All animals with acute EC had lost more than 8% of original
weight at day 3. At day 7, control animals showed a significant
weight loss (−55%) as compared with the other groups. The
drug-eluting platform with IFX or VDZ showed a significant
weight recovery in comparison with CoverGel without bioactive
drug (−17 and −20 vs. −36%; p < 0.044) (Figure 6A). BT to
liver at day 7 was absent in sham animals. The Control group
presented a significantly higher BT as compared with CoverGel
+ IFX and CoverGel + VDZ (100 vs. 14.3 and 16.6%; p < 0.05).
Animals treated with CoverGel showed a decreased BT (62.5%)
without statistical differences (Figure 6B). The histological score
for groups with EC was comparable: Control 5.87 ± 0.35,
CoverGel 5.24 ± 0.76, CoverGel + IFX 5.34 ± 0.98, and
CoverGel + VDZ 5.28 ± 0.82 (Figure 6C). The ratio between
colon length and weight [median (range)], a simple indicator of
edema and inflammation in the tissue, was significantly higher
in control animals as compared with the other treatment groups
(Control vs. CoverGel, CoverGel + IFX and CoverGel + VDZ)
[0.3157 (0.244) g/cm vs. 0.2063 (0.1012) g/cm p= 0.0012, 0.1854
(0.1527) g/cm p = 0.0012 and 0.1914 (0.0545) g/cm p = 0.0013],
respectively (Figure 6D).
Chronic EC Animal Study
There was variation in both groups in the degree of colitis
induction throughout the 4 TNBS applications. Figure 7
shows representative endoscopic and macroscopic images of
both groups.
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FIGURE 3 | Cell viability of Caco-2 cells in conditioned medium with 1, 2, 5, 10, and 15% of CoverGel. Cells were cultured at 37◦C and 5% CO2 for 24, 48, 72, and
96 h. Values are expressed in Relative Fluorescence Units (RFU).
No statistically significant differences were observed in
ponderal evolution at any day of the study (Figure 8A), in BT to
liver (two animals out of six in each group, 33.3%) (Figure 8B),
and in the histological score for CoverGel + IFX (5.48 ± 0.55)
and IFX s.c. (4.96± 0.71) (Figure 8C). Colon weight/length ratio
at day 28 was significantly lower in the IFX subcutaneous treated
group compared to the group treated with CoverGel+ IFX (0.213
(0.124) vs. 0.3497 (0.129), p= 0.0087) (Figure 8D).
The evolution of levels of ATIs for each group is shown in
Figure 9. At day of euthanasia, levels of ATIs were significantly
lower in rats treated with CoverGel + IFX compared to rats
treated with IFX subcutaneously (0.90 ± 0.06 vs. 1.97 ± 0.66
µg/mL-c, p= 0.0025).
DISCUSSION
In this paper we have reported the development and
characterization of a new hydrogel, the feasibility of the
application of this hydrogel as a drug-eluting platform, and
the effectiveness of this platform to treat local inflammatory
lesions in the colon. This new hydrogel is based on Poloxamer
Pluronic-F127, Hyaluronic acid, and Methylcellulose which
present biocompatible, bioadhesive, and bioactive properties.
Alone, these three components of which our hydrogel is
composed have proven their biocompatibility among other
beneficial characteristics (10–14). HA is well-known for its
promotion of cellular viability which is thought to be via the
CD44 receptor and the IL6 pathway; this effect has also been
seen in tumor cells (15–17). This could represent a problem
since an inflammatory environment such as a UC increase
the risk of tumor development. However, despite this, HA
hydrogels loaded with antitumoral drugs have been very useful
in inducing cancer cell death (18) in truly tumor environments,
so we assumed that this cellular viability enhancement helps
in the mucosal restoration but would not be enough to cause
tumor development.
Mucosal lesions refractory to biological treatments in IBD
patients is a clinical challenge and unmet need that requires
new treatment modalities. Drug delivery directly to the colon
is an option, thanks to oral dosage formulations that are
designed to achieve a controlled drug release. However, this
controlled release has mainly been achieved with small molecules
but not for macromolecules, such as biologics (10). Direct
release in the colon is beneficial to prevent early absorption
of the drug, thus increasing the quantity of drug reaching
the target tissue and at the same time decreasing systemic
exposure and associated side-effects. A specific form of control
drug release is polymer-based drug delivery. Polymers offer a
wide range of possibilities useful for colonic delivery. These
polymers can be triggered to start releasing drug by physiological
characteristics of the healthy colon, as well as in different
disease situations (10). Hydrogels for drug delivery have also
been studied for their capacity of mucoadhesion and controlled
delivery (11).
Local injection of infliximab can be a novel scenario for
endoscopic therapy in IBD patients with symptomatic isolated
mucosal lesions, as has been proposed by our group (12).
The real efficacy of locally injected IFX is not discernible
from current literature, but available data seem encouraging
at a dose of 100mg per session, assuming that higher anti-
TNF concentrations given through local injection can favor
healing and prevent complications, because a trend for a dose–
response curve was observed. Topical injection of anti-TNF
agents has been described in the treatment of long-standing
perianal fistulizing CD in the absence of an abscess (2). There are
technical variations in topical injection of the anti-TNF agents.
The agents were injected in a circumferential or intrafistula
fashion via the external or internal.
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FIGURE 4 | In vivo biocompatibility study. (A) % of organ weight relative to total body weight after intraperitoneal injection of 10 mL/kg of CoverGel on rats.
represents control rats rats euthanized 3 days post injection and rats euthanized 7 days post injection. (B) Representative images of major organs H/E
stainings from each group at a 40 × zoom. (C) H/E staining images of tissue surrounding subcutaneously placed CoverGel after 10 days post placement (10 × left
image, 40 × right image). (D) Scanning electron microscopy images of hydrogel after 10 days post subcutaneous placement.
In this work, we have provided a new therapeutic tool for
endoscopy by developing a new hydrogel (CoverGel) based on
HA, MC, and F127, which presents biocompatible, bioadhesive,
and bioactive properties (13–17). CoverGel is an endoscopic
vehicle to locally deliver biological drugs (IFX and VDZ) with
proven efficacy in acute and chronic EC in rats. Moreover, the
endoscopic administration of IFX induces significantly lower
levels of ATI as compared with subcutaneous administration. The
rationale for the drug dosages used (1 mg/mL) with our drug-
eluting gel is based on previous clinical experience with local
injection of IFX (12).
Our developed hydrogel showed a reverse thermosensitive
capacity of gelation accompanied by a greater adhesion capacity.
When the hydrogel contacts the mucosal layer at a physiological
temperature, it gelifies permitting the adhesion to the mucosa
(18). Rheological studies in our hydrogel confirmed that it
is a non-Newtonian fluid, meaning that its viscosity varies
with temperature. Morphologically, our hydrogel presents a
macroporous (pore diameters > 50 nm) interconnected network
that can be the matrix for cell ingrowth as well as nutrients
and waste flow—essential characteristics for cell survival within
the hydrogel. This platform is less vulnerable to matrix
transformations due to osmotic pressure or tissue extrusion,
which is an advantage for a controlled drug release of the
hydrogel (19). Different kinetic models were studied with
the results obtained from the drug release experiments. The
kinetic model that best fitted our results was the Higuchi
release model. This model is explained by Fick’s law, in which
the diffusion of a molecule is related to its concentration.
The diffusion flux goes from a higher concentrated area to
a lesser concentrated one. The magnitude of the diffusion
flux will be proportional to the concentration gradient. These
results and kinetic model were confirmed when mechanistic of
drug release from Covergel were studied by the Korsmeyer-
Peppas model, confirming that the diffusion coefficient follows
a Fickian diffusion. Our hydrogel showed the capacity to
improve cellular viability in a dose-dependent manner at
least until a 10%, demonstrating a good potential to become
a cell carrier. Intraperitoneal injection stated that CoverGel
did not cause an acute toxicity reaction on animals 3 or 7
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FIGURE 5 | Endoscopic and macroscopic representative images of the acute EC animal model. Endoscopic images from day 3 (day of treatment) and day 7 (day of
euthanasia) and macroscopic image of day 7 (day of euthanasia) from two representative animals of each group.
days post intraperitoneal injection. Subcutaneous placement of
our hydrogel in rats was done to evaluate in vivo behavior
and biodegradability of our hydrogel, which was evaluated
by SEM, and we confirmed that the inner structure was
maintained 10 days after s.c. placement and no cell infiltration
was seen.
All of these results help us conclude that this hydrogel is a
good candidate to be used in the digestive system and implement
in endoscopic techniques in order to cover some unmet needs
of the field. Although in vitro and in vivo results are really
promising, further experiments on in vivo drug release kinetics
and degradation need to be performed, as these characteristics
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FIGURE 6 | Clinical evaluations on rats from the acute EC animal model. Color representations are as follows: Control group Sham group CoverGel group
CoverGel + IFX group and CoverGel + VDZ group. (A) Variation (1) of weight relative to day 0 (day of induction. (B) Bacterial translocation to the liver. (C)
Histological score. (D) Colon weight/length ratio. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001.
have previously been reported to vary from in vitro analysis to in
vivo, due to inflammatory cell response (20–22).
TNBS-induced colitis has been proven as a valid method
to elucidate different mechanisms underlying the mechanism
of the disease (23). Furthermore, and besides its limitations
mimicking all different aspects of this complex disease, which
are still unknown, this model is a great tool to study the
immunopathogenesis of the disease and the potential benefit of
different therapies (23).
Our results show that the simple application of our hydrogel
as a dressing on the inflamed tissue by means of a shield
improves the overall outcome and restoration of the mucosal
layer. This beneficial effect of CoverGel is based on its good
biocompatibility properties, able to improve mucosal healing.
However, when CoverGel is loaded with biological drugs with
proven efficacy treating this disease, the effect is even more
pronounced. In this sense, endoscopic response was obtained
after 4 days of treatment in all animals treated with CoverGel,
but unfortunately, histological remission was not achieved
at this time. Despite that we do not have measurements
of local and systemic levels of the drugs applied by the
hydrogel, clinical response was accompanied by different clinical
aspects such as body weight loss, colon weight/length ratio,
or bacterial translocation to the liver; all features improved
in the groups treated with CoverGel alone or in combination
with drugs.
The efficacy of an enema based on ascorbyl palmitate hydrogel
loaded with dexamethasone has been demonstrated in mice
with colitis as well as in the ex vivo analysis of colon samples
from patients with IBD (24). By contrast, our hydrogel, which
can be also administered as enema, has been designed to be
administered under an endoscopic view to perform a more
localized treatment. Another goal of our project was to improve
the patient developing resistance to anti-TNF agents, which
is one of the main problems associated with biologics. This
resistance is caused by the formation of antidrug antibodies
(ADAs), as a response of the body to these exogenous complex
proteins. The kind of mAbs most used in IBD, no matter their
nature, cause to a greater or lesser degree ADA formation (25).
Since new drug development is a complex and long-lasting
effort, new therapeutic approaches are needed to reduce this
risk and allow patients to continue on a successful therapy
longer. The direct drug administration with CoverGel was able
to significantly improve the disease outcome in an animal
model using a much lower dose than the standard dose
applied. Moreover, when we compared the formation of ATIs
from subcutaneous injection vs. CoverGel application in an
experimental model of chronic EC (with a longer period of
time of the disease state), we observed that whereas there were
no major significant differences on the outcome of the disease
between both ways of treatment application, the levels of ATIs
were significantly lower on the group treated with CoverGel.
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FIGURE 7 | Endoscopic and macroscopic representative images of the chronic EC animal model. Endoscopic images from day 3 (first treatment application), day 7
(second TNBS induction), day 21 (fourth TNBS induction), day 24 (fourth treatment application), and macroscopic image of day 28 (day of euthanasia).
These results confirmed our theory that a locally applied therapy
at a lower dose is able to obtain a good clinical result and at the
same time reduce adverse events and complications associated
with the systemic application of a drug.
Taken together, the results from our study, although
preliminary and preclinical, demonstrate that endoscopic
administration of a based-on hydrogel drug delivery platform
represents a safe and promising approach for the management
of active lesions with a lower dose as compared with systemic
administration. Present findings also suggest than levels of
ADAs are lower with this approach, opening the opportunity
to be used in patients with a past history of acute infusion
reactions to the drug. Further research, preclinical and clinical,
needs to be pursued to safely evaluate and introduce this
technique in standard practice to increase the pool of therapeutic
interventions to treat IBD patients. Direct drug administration
through endoscopy opens new possibilities for therapeutic
endoscopy, allowing for the application of bioactive treatments
in different pathologies already managed with endoscopy such as
colorectal cancer and local inflammatory lesions.
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FIGURE 8 | Clinical evaluations on rats from the acute EC animal model. Color representations are as follow: CoverGel + IFX group and IFX s.c. group. (A)
Variation (1) of weight relative to day 0 (day of induction). (B) Bacterial translocation to the liver. (C) Histological score. (D) Colon weight/length ratio. **p < 0.01.
FIGURE 9 | Evolution of antibodies to Infliximab (ATIs) in serum for: CoverGel + IFX group and IFX s.c. group. Graph represents the concentration of ATIs
(µg/mL-c calibrated in comparison to a polyclonal rabbit α-IgG standard). *p < 0.05.
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